The Growing Challenge of Variants of Uncertain Significance in Clinical Genomics

Clinical genomics has revolutionized the diagnosis and management of genetic disorders, enabling precision medicine tailored to an individual's DNA. Yet as whole-exome and whole-genome sequencing become routine, clinicians increasingly encounter a perplexing category of genetic findings: variants of uncertain significance (VUS). These alterations in the genome have an unknown impact on health, and they represent one of the most formidable bottlenecks in translating genomic data into actionable clinical insights. The sheer volume of VUS reported in diagnostic testing, combined with the complexity of interpreting their functional consequences, demands a rigorous, data-driven approach to reduce uncertainty and improve patient outcomes.

Defining Variants of Uncertain Significance

Variants of uncertain significance are genetic changes for which there is insufficient evidence to classify them as either pathogenic (disease-causing) or benign (harmless). According to guidelines from the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology, VUS fall into the middle of a five-tier classification system: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. This ambiguity creates a gray area that complicates clinical decision-making. For patients, receiving a VUS result can trigger anxiety, confusion, and sometimes unnecessary medical interventions if the variant is incorrectly presumed to be harmful. For clinicians, interpreting VUS requires weighing conflicting evidence from population databases, computational predictions, and familial segregation studies.

In many clinical laboratories, VUS constitute a significant proportion of reported variants—often 20–40% of all findings in a typical exome or genome test. The frequency of VUS is higher in individuals from underrepresented populations, due to a lack of reference data, and in genes that are not well-characterized functionally. As sequencing technology becomes more affordable and widespread, the number of novel variants identified continues to outpace the capacity for functional validation, making VUS a persistent challenge.

Core Challenges in Interpreting VUS

1. Insufficient Evidence from Population and Functional Studies

The most fundamental obstacle is the lack of data. For a variant to be classified with confidence, evidence is needed from large, diverse population cohorts showing its allele frequency, as well as from functional assays that measure its biological effect. Many VUS are extremely rare—observed in only a single individual or family—making it nearly impossible to draw statistical conclusions. Even when population frequency data exists, it may not be enough to rule out pathogenicity, especially for recessive disorders or late-onset conditions. Functional studies, while definitive, are time-consuming, expensive, and cannot be performed for every novel variant. Consequently, most VUS remain in limbo indefinitely.

2. Genetic and Phenotypic Heterogeneity

Variants do not act in isolation. The same DNA change can have different effects depending on an individual's genetic background, environmental exposures, and epigenetic modifications. For example, a variant in the BRCA1 gene that is benign in most populations might be pathogenic when combined with a second modifier variant elsewhere in the genome. Moreover, many genetic disorders exhibit variable expressivity and incomplete penetrance—meaning that even a known pathogenic variant does not always cause disease. This complexity makes it difficult to assign a definitive classification to a VUS, as the same variant could be benign in one context and pathogenic in another.

3. Rapid Discovery Rate and Database Lag

Next-generation sequencing generates thousands of new variants per individual. As the global sequencing effort expands, the rate of variant discovery far exceeds the pace at which databases such as ClinVar, gnomAD, and HGMD can be curated and updated. Many VUS remain classified as uncertain simply because the relevant evidence has not yet been deposited or re-evaluated. Furthermore, discrepancies between databases—where one source labels a variant as benign and another as VUS—add another layer of confusion for clinicians trying to interpret results.

4. Technical Limitations and Sequencing Artifacts

Not all sequencing platforms are created equal. Base-calling errors, mapping inaccuracies, and coverage gaps can introduce false variants that appear to be VUS. Low-quality reads in repetitive or GC-rich regions are particularly prone to errors. Additionally, copy number variants, structural rearrangements, and mosaic variants may be missed or mischaracterized by standard short-read sequencing. These technical artifacts waste resources and can lead to incorrect clinical decisions if not properly filtered out.

5. Inconsistent Classification Practices Across Laboratories

Despite ACMG guidelines, interlaboratory variability in VUS classification is well documented. Different labs may apply the same scoring criteria differently, weigh evidence sources inconsistently, or update classifications at different intervals. This lack of harmonization means that a variant classified as VUS in one lab might be called likely benign in another. For patients who undergo testing at multiple facilities or who transfer care, this inconsistency can be a source of confusion and potential misdiagnosis.

Strategies to Address the VUS Challenge

Leveraging Large-Scale Population Databases

Resources like the Genome Aggregation Database (gnomAD) have transformed variant interpretation by providing allele frequency data from over 140,000 individuals. If a variant is common in the general population, it is less likely to be pathogenic for a rare Mendelian disorder. Conversely, ultra-rare or novel variants are prioritized for further investigation. Efforts to increase diversity in these databases are critical, as current datasets are disproportionately skewed toward individuals of European ancestry, leaving many populations underrepresented.

Advanced Computational Prediction Tools

Bioinformatics algorithms such as SIFT, PolyPhen-2, CADD, and REVEL combine multiple genomic features—evolutionary conservation, protein structure, nucleotide context—to estimate the likelihood that a variant is damaging. While these tools are not perfectly accurate, they provide a valuable triage step, flagging high-priority variants for functional follow-up. Machine learning models trained on large sets of validated variants continue to improve, but they still require careful calibration to avoid overfitting and bias.

Functional Assays and High-Throughput Screening

Laboratory experiments that directly measure the effect of a variant on protein function, splicing, or gene expression remain the gold standard for classification. Techniques like saturation mutagenesis, CRISPR-based editing, and multiplexed functional assays allow hundreds or thousands of variants to be tested simultaneously. For example, the BRCA1 and BRCA2 variant functional assays have reclassified many VUS to either benign or pathogenic, directly impacting clinical management. Extending these high-throughput approaches to other genes is a major research priority.

Data Sharing and Collaborative Initiatives

No single institution can resolve all VUS alone. International consortia such as the ClinGen project and the Global Alliance for Genomics and Health (GA4GH) promote the sharing of variant interpretations, evidence, and expert consensus. The ClinVar database aggregates submissions from laboratories worldwide, enabling users to see when classifications have been updated or disputed. Encouraging mandatory submission of VUS data as part of clinical testing would accelerate reclassification and reduce duplication of effort.

Periodic Re-Evaluation and Patient Recontact

Because knowledge evolves, a VUS today may be reclassified tomorrow. Clinical guidelines recommend that laboratories and clinicians periodically review VUS interpretations, particularly when new evidence emerges. Some institutions have implemented automated alert systems that notify providers when a VUS is reclassified. However, the responsibility for recontacting patients raises ethical and logistical questions—who bears the cost, and how far back in time should one go? Clear policies and workflows are needed to ensure that patients benefit from updated interpretations.

Future Directions in VUS Resolution

Integration of Transcriptomics and Proteomics

RNA sequencing can reveal whether a DNA variant affects splicing, transcript abundance, or isoform usage—information that is often invisible from DNA alone. Similarly, proteomic profiling can detect changes in protein levels or post-translational modifications. Combining these "multi-omics" data with genomic sequencing is a powerful strategy to clarify the functional impact of VUS, especially in genes with complex regulation.

Artificial Intelligence and Deep Learning

Deep learning models, such as neural networks trained on millions of variants with known outcomes, are achieving higher accuracy than traditional rule-based predictors. These models can incorporate nonlinear interactions between features and learn from population-scale data. However, they also risk being black boxes—clinicians may be uncomfortable acting on predictions without mechanistic understanding. Explainable AI frameworks are under development to provide interpretable outputs alongside predictions.

Long-Read Sequencing and Structural Variant Detection

Many VUS are actually misclassified because short-read sequencing fails to resolve complex structural variants, repetitive elements, or phased haplotypes. Long-read technologies (PacBio, Oxford Nanopore) can span large genomic regions, enabling accurate detection of insertions, deletions, inversions, and tandem repeats. As long-read sequencing becomes cheaper and more accessible, it will help resolve a subset of VUS that are actually due to structural changes rather than single-nucleotide substitutions.

Patient and Clinician Education

Ultimately, the best tools are only as good as the people using them. Clinicians need ongoing training in genomic interpretation to understand the limitations of VUS classifications and how to communicate uncertainty to patients. Decision support tools embedded in electronic health records can provide curated information and risk estimates at the point of care. Patients, too, benefit from genetic counseling that explains the meaning of a VUS, the likelihood of reclassification, and the options for follow-up testing.

Conclusion

Variants of uncertain significance are an inevitable byproduct of the current state of genomic knowledge. They reflect both the power of large-scale sequencing and the gaps in our understanding of the human genome. Addressing the VUS challenge requires a multifaceted approach: expanding population databases, improving computational predictions, scaling functional assays, fostering data sharing, and developing policies for periodic re-evaluation. As these efforts converge, the proportion of VUS is expected to decline, and the clinical utility of genomic testing will continue to grow. For now, careful interpretation and transparent communication remain the cornerstones of responsible patient care in the era of genomic medicine.